

Lathyrane, Premyrinsane, and Related Diterpenes from *Euphorbia boetica*: Effect on in Vitro Neural Progenitor Cell Proliferation

Eugenia Flores-Giubi,^{†,‡} Noelia Geribaldi-Doldán,[§] Maribel Murillo-Carretero,^{§,⊥} Carmen Castro,^{*,§} Rosa Durán-Patrón,^{†,⊕} Antonio J. Macías-Sánchez,^{*,†,‡,⊕} and Rosario Hernández-Galán^{†,‡,⊕}

[†]Departamento de Química Orgánica, Facultad de Ciencias, Campus Universitario Puerto Real s/n, Universidad de Cádiz, 11510 Puerto Real, Cádiz, Spain


[‡]Instituto de Investigación en Biomoléculas (INBIO), Universidad de Cádiz, 11510 Puerto Real, Cádiz, Spain

[§]Área de Fisiología, Facultad de Medicina, Universidad de Cádiz, and Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), 11510 Puerto Real, Cádiz, Spain

[⊥]Departamento de Química Biológica, Facultad de Ciencias Químicas, Universidad Nacional de Asunción, San Lorenzo, Departamento Central, Paraguay

Supporting Information

ABSTRACT: Lathyrane-type diterpenes previously have been proven to promote proliferation of neural precursor cells (NPCs) by targeting and activating one or more protein kinase C (PKC) isozymes. Aiming to find new drug candidates with a lathyrane skeleton to modulate adult neurogenesis through PKC activation, a phytochemical study of a methanol extract of the aerial parts of *Euphorbia boetica* was carried out. Seven new diterpenes, representing the premyrsinane (1–3), myrsinane (4, 5), and cyclomyrsinane types (6, 7), along with three known diterpenes, belonging to the cyclomyrsinane (8) and lathyrane types (9, 10), were isolated. The chemical structures and relative configurations of the new compounds were determined by extensive NMR spectroscopic studies and comparison with known compounds. The absolute configurations for compounds 2, 3, 6, and 7 were proposed, based on a comparison of the experimental ECD spectra of compounds 2 and 7 with those of known related compounds. The activity of lathyrane compounds 9 and 10 as promoters of NPC proliferation was evaluated using a neurosphere assay. Both compounds increased the size of neurospheres in a dose-dependent manner when proliferation was stimulated by the epidermal growth factor and the basic fibroblast growth factor.



Plants of the genus *Euphorbia* (Euphorbiaceae) are well known for the extraordinary chemical diversity of their diterpenoids and the wide variety of pharmacological properties they possess.^{1–3} In particular, diterpenes with tiglane, ingenane, and lathyrane skeletons, frequently found in plants of this genus, are known protein kinase C (PKC) activators. They bind to their regulatory domain, mimicking the effect of their physiological activator diacylglycerol.⁴ PKC modulation has been linked to a number of relevant physiological events of interest.

Highly lipophilic phorbol esters (tiglane-type diterpenes), despite their ability to activate PKC, are deemed unsuitable for therapeutic applications as a consequence of their strong tumor-promoting activities.⁵ In contrast, 12-deoxyphorbols, like prostratin or 12-deoxyphorbol-13-phenylacetate, which are less lipophilic, activate PKC without being tumor promoters.^{6,7} Prostratin and related tiglane esters are potentially useful in the treatment of HIV-1, in combination with antiretroviral therapies,^{8,9} since they reactivate replication of latent viral

reservoirs in CD4⁺ T-cells,¹⁰ by activating NF-κB through a PKC-dependent pathway.^{11,12} Some lathyrane-type diterpenes also mimic prostratin in their ability to reactivate HIV-1 latency¹³ through a PKC-dependent pathway.¹⁴ On the other hand, it has been proven that 12-deoxyphorbols, like prostratin or 12-deoxyphorbol-13-phenylacetate, and lathyrans, such as 3,12-di-*O*-acetyl-8-*O*-tigloylingol, promote proliferation of neural precursor cells (NPCs) by targeting and activating one or more PKC isozymes.^{15,16} Given the limited ability of the brain to generate neurons in damaged brain areas, compounds promoting NPC proliferation may be suitable for the development of therapies aimed to replace dead neurons in patients with disorders that occur with neuronal death.

Previous studies have shown that lathyrane-type diterpenes with very similar structures differ significantly in their ability to activate PKCs and promote NPC proliferation.¹⁶ Therefore, it

Received: April 13, 2019

Published: September 11, 2019

is important to shed some light on the structural features that contribute to the activity of this type of compound, as well as to their mechanism of action in the interaction with the molecular target.

In the framework of ongoing phytochemical research on *Euphorbia* species, aimed at isolating new bioactive compounds with biological properties related to their ability to modulate PKC isozymes, attention was focused on *Euphorbia boetica* Boiss., an herb endemic to Europe, which is distributed widely in the southern part of the Iberian Peninsula. It is known to produce a large amount of latex, which causes irritation of the human skin. In previous studies, Ferreira et al. described the isolation from this plant of the triterpenes boeticol and euphol,¹⁷ some steroids,¹⁸ a premyrsinane-type diterpene,¹⁸ a lathyril derivative named euphoboetirane A,¹⁹ and 6,17-epoxylathyrane-type diterpenes, known as epoxyboetiranes A, B, K, L, and M.²⁰


In order to find new potential PKC activators with a lathyrane skeleton and study their ability to promote NPC proliferation, the chemical constituents of *E. boetica* were re-examined. This paper reports on the isolation and structural elucidation of seven new diterpenes from this plant, belonging to the premyrsinane (1–3), myrsinane (4, 5), and cyclomyrsinane types (6, 7), together with three known diterpenes, belonging to the cyclomyrsinane (8) and lathyrane types (9, 10). Their chemical structures were established on the basis of the interpretation of their spectroscopic data, including HRESIMS and 1D and 2D NMR. In addition, the biological activity of lathyranes 9 and 10 as facilitators of NPC proliferation is described.

RESULTS AND DISCUSSION

E. boetica was re-collected at “El Pinar del Hierro” in Chiclana de la Frontera, Cádiz (Spain). The aerial parts of the fresh plant were used to obtain a methanol extract, which was partitioned with hexane and dichloromethane, as indicated in the Experimental Section. Both fractions were fractionated by silica gel column chromatography and further purified by HPLC, to afford seven new (1–7) and three known (8–10) diterpenoids. The known compounds were identified by comparison of their spectroscopic data with those reported in the literature as a pentacyclic diterpenoid ester of cyclomyrsinane type, isolated from *E. teheranica* (8),²¹ epoxyboetirane A (9) isolated previously from *E. boetica*,²⁰ and 3,5,15-tri-*O*-acetylthyril (10), also known as euphoboetirane A, and isolated from *E. boetica*,¹⁹ *E. lathyris*,²² and *E. insularis*.²³

Compounds 1–3 showed spectroscopic data structurally closely related to diterpenes with a premyrsinane skeleton. Premyrsinanes are a group of tetracyclic or alternatively pentacyclic diterpenes as a consequence of the formation of a tetrahydrofuran ring by intramolecular cyclization involving carbons C-12, C-6, C-13, and C-17.¹

Compound 1 was isolated as an amorphous solid with a molecular formula of C₂₆H₃₆O₈, as deduced from the HRESIMS analysis (*m/z* 499.2322 [M + Na]⁺, calcd for C₂₆H₃₆O₈Na, 499.2308). Its spectroscopic data (Table 1) were in accord with a pentacyclic structure similar to that proposed for karajinone A (11), previously isolated from *E. decipiens*.²⁴ The main difference between the ¹H NMR spectrum of 1 and that of the previously described premyrsinane 11 was the presence of two signals at δ_H 0.96 and 1.54 ppm in 1 (Table 1), which correlated to a methylene group at δ_C 30.1 ppm in



the gHSQC experiment. This methylene group was assigned to C-7 because of its correlation with the proton signal H-17b at δ_H 3.56 ppm in the gHMBC spectrum. These data, together with the absence of aromatic signals, suggested that the benzoyl substituent at C-7 in karajinone A (11) was replaced by a hydrogen atom in 1. In addition, the ¹H NMR spectrum of 1 showed the presence of an extra methyl group at δ_H 1.06 ppm (s). This singlet was connected to a primary carbon at δ_C 28.0 ppm (C-18) and to four other carbons at δ_C 25.6 (C-9), 18.4 (C-10), 19.7 (C-11), and 15.9 ppm (C-19) in the gHMBC experiment. These correlations showed that the additional methyl group is attached to C-10 and replaced the acetoxymethyl group of karajinone A (11).

The relative configuration of 1 was elucidated on the basis of those described for previously reported natural premyrsinane diterpenes^{24–26} and correlations observed in the NOESY

Table 1. NMR Spectroscopic Data of Premyrsinanes 1–3 in CDCl₃ (*J* in Hz)

position	1		2		3	
	δ_{H} (500 MHz)	δ_{C} (125 MHz), type	δ_{H} (500 MHz)	δ_{C} (125 MHz), type	δ_{H} (400 MHz)	δ_{C} (100 MHz), type
1 α	3.47, dd (15.0, 10.0)	42.1, CH ₂	3.18, dd (8.0, 13.5)	42.8, CH ₂	3.17, dd (8.0, 13.6)	42.8, CH ₂
1 β	1.39, dd (15.0, 10.0)		1.67, t (13.5)		1.63, dd (13.6)	
2 α	2.11, m	36.2, CH	1.90, m	37.2, CH	1.84, m	37.4, CH
3 α	5.35, t (4.0)	78.1, CH	5.36, t (3.8)	78.4, CH	5.21, t (3.4)	78.5, CH
4 α	2.42 dd (11.0, 4.0)	52.3, CH	2.43, dd (11.5, 3.8)	50.3, CH	2.38, dd (11.4, 3.4)	50.4, CH
5 β	5.44, d (11.0)	70.4, CH	6.46, d (11.5)	69.9, CH	6.25, d (11.4)	68.9, CH
6		52.9, C		48.1, C		47.6, C
7a	1.54, m	30.1, CH ₂	β : 4.97, d (6.0)	70.3, CH	β : 4.68, d (6.8)	70.6, CH
7b	0.96, m					
8 α	1.75, m	17.6, CH ₂	2.19, m	22.3, CH ₂	2.25, m	22.3, CH ₂
8 β	0.80–0.87, m		1.93, m		1.90, m	
9 α	0.80–0.87, m	25.6, CH	0.79–0.76, m	18.9, CH	0.80–0.75, m	18.9, CH
10		18.4, C		18.4, C		18.3, C
11 α	0.63, t (7.5)	19.7, CH	0.79–0.76, m	23.8, CH	0.80–0.75, m	23.8, CH
12 β	2.25, d (7.5)	39.3, CH	3.58, d (6.7)	35.2, CH	3.46, d (6.3)	34.9, CH
13		88.2, C		85.6, C		85.7, C
14		201.9, C		204.1, C		204.2, C
15		90.0, C		84.2, C		84.0, C
16 β	0.90, d (7.0)	14.3, CH ₃	0.87, d (6.5)	13.8, CH ₃	0.89, d (6.8)	14.1, CH ₃
17a	4.06, d (9.3)	74.7, CH ₂	5.04, d (11.5)	63.6, CH ₂	4.88, d (12.0)	64.3, CH ₂
17b	3.56, d (9.3)		4.55, d (11.5)		4.51, d (12.0)	
18 α	1.06, s	28.0, CH ₃	1.06, s	29.4, CH ₃	1.06, s	29.5, CH ₃
19 β	0.99, s	15.9, CH ₃	0.97, s	14.9, CH ₃	0.95, s	14.8, CH ₃
20 β	1.51, s	20.0, CH ₃	1.77, s	24.9, CH ₃	1.73, s	24.5, CH ₃
OCO-3		171.0, ^b C		170.3, ^c C		170.6, ⁱ C
OCOMe-3	2.07, s ^a	21.0, ^c CH ₃	1.92, s ^d	21.3, ^f CH ₃	2.11, s ^g	21.3, ^j CH ₃
OCO-5		170.5, C		165.2, C		175.0, C
OCOMe-5	2.02, s	21.1, CH ₃				
OCOBz-5						
1'				129.3, C		
2', 6'			7.70, d (7.9)	129.3, CH		
3', 5'			7.01, m	128.0, CH		
4'			7.15, t (7.9)	132.8, CH		
OCOiBu-5						
2'					2.15, m	33.9, CH
3'					0.92, d (6.8) ^h	18.5, ^k CH ₃
4'					0.88, d (6.8) ^h	18.4, ^k CH ₃
OCO-7				170.1, C		169.9, C
OCOMe-7			2.17, s	21.3, ^f CH ₃	2.12, s	21.2, CH ₃
OCO-13				170.7, ^c C		170.9, ⁱ C
OCOMe-13			2.12, s ^d	20.9, ^f CH ₃	2.01, s ^g	21.3, ⁱ CH ₃
OCO-15		170.0, ^b C				
OCOMe-15	2.09, s ^a	21.6, ^c CH ₃				
OH-15			4.46, s		4.47, s	
OCONic-17				164.8, C		164.8, C
1''				125.1, C		125.1, C
2''			8.83, d (2.0)	150.6, CH	9.17, d (1.6)	150.5, CH
4''			8.53, dd (5.0, 2.0)	153.1, CH	8.82, dd (5.0, 1.6)	153.9, CH
5''			6.99, m	123.0, CH	7.43, dd (8.0, 5.0)	123.7, CH
6''			7.60, dt (8.0, 2.0)	136.0, CH	8.19, dt (8.0, 1.6)	136.7, CH

^{a–j}Interchangeable signals.

experiment. The premyrsinane skeleton is based on a *trans*-fused 5/7/6-tricyclic ring system and one *cis*-fused three-membered ring. In this, the 13,17-epoxy ring, H-4, H-9, and H-11 are α -oriented, and H₃-16 and H-12 are β -oriented. NOESY correlations observed for H-1 α /H-2 α , H-2 α /H-3 α , H-3 α /H-4 α , H-9 α /H-11 α , and H-11 α /H₃-18 α indicated that these protons are directed inward in the premyrsinane skeleton,

whereas the correlations of H-1 β /H₃-16 β , H-5 β /H-12 β , and H-12 β /H₃-19 β were used to place these protons on the opposite face of the skeleton (Figure 1). NOESY correlations of H₃-19 β with H-12 β and of H₃-18 α with H-11 α , where both methyl groups are substituted on the same carbon (C-10), are consistent with the proposed relative configuration for the *gem*-dimethylcyclopropane moiety (Figure 1). These correlations




Figure 1. Selected NOESY correlations exhibited by 1.

allowed **1** to be assigned as $(2S^*,3S^*,4R^*,5R^*,6R^*,9S^*,11S^*,12R^*,13R^*,15R^*)$ -3,5,15-triacetoxy-13,17-epoxy-premyrsinol.

Compounds **2** and **3** were isolated as amorphous solids with respective molecular formulas of $C_{39}H_{45}NO_{12}$, according to the ion peak at m/z 742.2855 $[M + Na]^+$ (calcd for $C_{39}H_{45}NO_{12}Na$, 742.2839), and $C_{36}H_{47}NO_{12}$, according to the ion peak at m/z 708.3009 $[M + Na]^+$ (calcd for $C_{36}H_{47}NO_{12}Na$, 708.2996). After a perusal of the 1H and ^{13}C NMR data, part of the unsaturations deduced from their respective elemental formulas could be assigned to up to five carbonyl groups for both compounds, with two aromatic rings for compound **2** and one for compound **3**. A comparison of their spectroscopic data (Table 1) with those of diterpenes from other *Euphorbia* spp. showed that they were very similar to those described for proliferpene B (**12**), previously isolated from *E. prolifera*,²⁵ suggesting the presence of a common diterpene skeleton, while differences in the substituents and relative configurations were observed.

As mentioned above, analysis of ^{13}C NMR spectra for compounds **2** and **3** revealed the presence of five signals corresponding to the resonances of ester carbonyl carbons. Based on their gHSQC and gHMBC spectra, they corresponded, in both compounds, to the presence of three acetate esters and a nicotinate ester substituted at C-3, C-7, C-13, and C-17, respectively. The long-range couplings of the protons H₂-17 (δ_H 5.04 ppm in **2** and 4.51 and 4.88 ppm in **3**) with the carbonyl carbons OCO-17 (164.8 ppm in **2** and **3**) in the gHMBC spectra demonstrated that a nicotinoyloxy group is located at C-17 in each compound. Furthermore, the presence of a free hydroxy group at C-15 was confirmed by gHMBC correlations between the proton of the hydroxy group (δ_H 4.46 ppm in compound **2**, δ_H 4.47 ppm in compound **3**) and carbons C-4, C-14, and C-15 (δ_C 50.3, 204.1, and 84.2 ppm in compound **2**, δ_C 50.4, 204.2, and 84.0 ppm in compound **3**, respectively).

On the other hand, while an ester group in both compounds is present at position C-5, their nature was different. For compound **2**, analysis of 1D and 2D NMR spectra showed the presence of a benzoate ester, while in compound **3** these data pointed to the presence of an isobutyrate ester. The long-range coupling between H-5 (δ_H 6.46 ppm in **2** and 6.25 ppm in **3**) and OCO-5 (δ_C 165.2 ppm in **2** and 175.0 ppm in **3**) in the

gHMBC spectra placed the ester group at C-5 in both compounds.

The relative configuration of compounds **2** and **3** was elucidated on the basis of comparison with previously reported natural premyrsinane diterpenes, such as proliferpene B (**12**),²⁵ and the correlations observed in the NOESY experiments. NOESY correlations were observed in both compounds for H-1 α /H-2 α , H-2 α /H-3 α , H-3 α /H-4 α , H-4 α /H₃-20 α , H-4 α /H-17a, H-17a/H-20 α , H-17b/H-20 α , H-17b/H-9 α , and H-17b/H-11 α and indicated that these protons are directed inward in the premyrsinane skeleton, whereas the correlations of H-1 β /H₃-16 β , H-5 β /H-7 β , H-5 β /H-12 β , H-12 β /15-OH, and H-12 β /H₃-19 β were used to place these protons on the opposite face of each molecule (Figures 2 and 3). Therefore, H-4, the H₂-17




Figure 2. Selected NOESY correlations exhibited by 2.




Figure 3. Selected NOESY correlations exhibited by 3.

methylene group at C-6, H-9, H-11, and H₃-18 are α -oriented, while H-12, OH-15, H₃-16, and H₃-19 are β -oriented. On the other hand, for compounds **2** and **3**, the configuration at C-7 is epimeric to that of proliferpene B (**12**),²⁵ based on the NOESY correlations for H-7 β /H-5 β in each compound. Assignment of the relative configuration at C-7 for both compounds based on a comparison of H-7 coupling constants with those of proliferpene (**12**)²⁵ was not conclusive, as in compounds **2**, **3**, and **12** a nearly bisected conformation of H-7 with H-8a and H-8b could be found. These correlations allowed **2** to be proposed as $(2S^*,3S^*,4R^*,5R^*,6R^*,7S^*,9S^*,11S^*,12R^*,13S^*,15R^*)$ -3,7,13-triacetoxy-5-benzoyloxy-17-nicotinoyloxy-premyrsinol and compound **3** as $(2S^*,3S^*,4R^*,5R^*,6R^*,7S^*,9S^*,11S^*,12R^*,13S^*,15R^*)$ -

3,7,13-triacetoxy-5-isobutyroxyloxy-17-nicotinoyloxy-premyrsinol.

Compounds **4** and **5** showed characteristic spectroscopic patterns for diterpenes with a myrsinane skeleton, which have a 5/7/6-tricyclic or alternatively a 5/7/6/5-tetracyclic carbon framework if a hemiacetal ring or a 13/17-epoxy is present. The ^1H and ^{13}C NMR spectra of both compounds (**4** and **5**) were similar (Table 2). In addition to the signals for the ester moieties, their ^{13}C NMR spectra showed signals for 20 carbons with chemical shifts similar to those of 14-deoxomyrsinols,^{27–29} suggesting that these compounds are polyesters of the same parent alcohol.

Table 2. NMR Spectroscopic Data of Myrsinanes **4** and **5** in CDCl_3 (J in Hz)

position	4		5	
	δ_{H} (600 MHz)	δ_{C} (150 MHz), type	δ_{H} (500 MHz)	δ_{C} (125 MHz), type
1 α	2.50, dd (15.9, 8.7)	43.4, CH ₂	2.48, dd (15.8, 9.3)	43.2, CH ₂
1 β	2.76, dd (15.9, 11.1)		2.74, dd (15.8, 10.8)	
2 α	2.11, m	36.6, CH	2.13, m	36.8, CH
3 α	5.22, t (3.6)	77.0, CH	5.15, t (3.8)	76.5, CH
4 α	3.04, dd (11.4, 3.6)	51.6, CH	2.95, dd (11.4, 3.8)	51.7, CH
5 β	5.86, dd (11.4, 1.8)	69.2, ^b CH	5.96, d (11.4)	69.5, CH
6		54.3, C		56.7, C
7 α	4.79, d (6.4)	63.8, CH	5.01, d (6.0)	63.4, CH
8	6.11, ddd (9.6, 6.4, 1.5)	123.4, CH	6.01, ddd (10.0, 6.0, 2.0)	123.1, CH
9	5.82, dd (9.6, 5.4)	133.2, CH	5.75, dd (10.0, 4.5)	133.8, CH
10		147.2, C		147.1, C
11 α	3.11, m	41.2, CH	3.23, m	42.8, CH
12 β	3.11, m	40.8, CH	3.17, d (5.5)	37.6, CH
13		89.0, C		91.4, C
14 α	4.96, s	81.0, CH	4.96, s	79.6, CH
15		89.8, C		89.7, C
16 β	0.82, d (7.2)	14.1, CH ₃	0.82, d (7.0)	14.2, CH ₃
17a	3.97, d (8.6)	69.1, ^b CH ₂	6.31, s	97.6, CH
17b	3.49, dd (8.6, 1.8)			
18a	4.82, brs	112.0, CH ₂	4.88, brs	112.7, CH ₂
18b	4.73, brs		4.85, brs	
19	1.81, s	20.8, CH ₃	1.78, s	19.7, CH ₃
20 β	1.23, s	24.4, CH ₃	1.34, s	24.5, CH ₃
O $\overline{\text{C}}\text{O}$ -3		171.0, ^c C		170.8, ^g C
OCOMe-3	1.99, s ^a	21.0, ^d CH ₃	2.01, s ^e	21.0, ^h CH ₃
O $\overline{\text{C}}\text{O}$ -5		169.3, C		169.0, C
OCOMe-5	1.96, s	20.8, CH ₃	2.00, s ^f	21.4, ⁱ CH ₃
O $\overline{\text{C}}\text{O}$ -7		170.5, C		170.1, C
OCOMe-7	1.94, s	21.0, CH ₃	1.98, s ^f	21.3, ^j CH ₃
O $\overline{\text{C}}\text{O}$ -14		170.3, C		170.1, C
OCOMe-14	2.02, s	20.9, CH ₃	1.98, s ^f	20.8, ⁱ CH ₃
O $\overline{\text{C}}\text{O}$ -15		168.4, ^c C		168.2, ^g C
OCOMe-15	2.06, s ^a	22.3, ^d CH ₃	2.08, s ^e	22.4, ^h CH ₃
O $\overline{\text{C}}\text{O}$ -17				169.7, C
OCOMe-17			1.98, s ^f	20.7, ⁱ CH ₃

^{a–i}Interchangeable signals.

Compound **4** was isolated as a colorless oil with a molecular formula of $\text{C}_{30}\text{H}_{40}\text{O}_{11}$, according to the ion peak at m/z 599.2484 $[\text{M} + \text{Na}]^+$ (calcd for $\text{C}_{30}\text{H}_{40}\text{O}_{12}\text{Na}$, 599.2468). The ^1H and ^{13}C NMR spectra showed signals for five acetoxy groups (Table 2), one more than for 3 β -O-propionyl-5 α ,7 β ,14 β ,15 β -tetra-O-acetyl-14-deoxomyrsinol (**13**), isolated previously from *E. prolifera*.²⁸ The positions of these acetyl groups were deduced from the gHMBC spectrum. Correlations of the protons at δ_{H} 5.86 (H-5), 4.79 (H-7), and 4.96 ppm (H-14) with the carbonyl carbons at δ_{C} 169.3 (O $\overline{\text{C}}\text{O}$ -5), 170.5 (O $\overline{\text{C}}\text{O}$ -7), and 170.3 ppm (O $\overline{\text{C}}\text{O}$ -14), respectively, demonstrated the locations of these three acetoxy groups at C-5, C-7, and C-14. However, there were no long-range correlations of protons to the carbonyl carbons of the two remaining acetyl groups. On the basis of the chemical shifts of the proton H-3 (δ_{H} 5.22 ppm) and the carbon C-3 (δ_{C} 77.0 ppm) and comparison with the data for compound **13**,²⁸ one of the two residual acetoxy groups was assigned at C-3, suggesting that the C-3 propoxy moiety in **13** has been replaced by an acetoxy group in compound **4**. Consequently, the remaining acetyl group could only be located at the C-15 quaternary carbon, which was confirmed by comparing the chemical shift of this carbon in **4** (δ_{C} 89.8 ppm) with that of **13** (δ_{C} 89.7 ppm).

The relative configuration of compound **4** was established by analysis of the ROESY spectrum and that described for the previously reported myrsinane diterpenes.^{1,2} Myrsinol diterpenes show a *trans*-fused 5/7/6-tricyclic ring system, α -orientations for the epoxy ring and H-4, and β -orientations for H₃-16 and the side chain at C-11.^{27–29} ROESY correlations observed for H-1 α /H-2 α , H-1 α /H-14 α , H-2 α /H-3 α , H-3 α /H-4 α , H-7 α /H-17a, H-7 α /H-17b, H-1 β /H₃-16 β , H-5 β /H-12 β , and H-12 β /H₃-20 β suggested that H-2, H-3, H-4, H-7, and H-14 are α -oriented (directed inward in the premyrsinane skeleton) and H-5, H-12, H-20, and H₃-16 are β -oriented (opposite face of the skeleton) (Figure 4). On the other hand,




Figure 4. Selected ROESY correlations exhibited by **4**.

ROESY correlations observed for H-12 β /H₃-19, H₃-19/H-18a, H-18a/H-18b, H-18b/H-11 α , H-11 α /H-9, H-9/H-8, and H-8/H-7 α confirmed, in turn, that H-11 is α -oriented, as well as H-7. These assignments were consistent with the relative configurations of the reported myrsinane diterpenes and allowed compound **4** to be established as (2*S**,3*S**,4*R**,5*R**,6*R**,7*R**,11*S**,12*R**,13*R**,14*S**,15*R**)-3,5,7,14,15-pentaacetoxy-14-deoxy-13,17-epoxymyrsinol.

Compound **5** was isolated as an amorphous solid and exhibited a $[M + Na]^+$ ion in its HRESIMS at m/z 657.2524 (calcd for $C_{32}H_{42}O_{13}Na$, 657.2523), providing the molecular formula $C_{32}H_{42}O_{13}$. Its spectroscopic data (Table 2) were in agreement with a tetracyclic structure of a 14-deoxomyrsinol, similar to **4**. The main differences between compounds **5** and **4** were the presence of an additional acetyl group and the lack of the signals for the diastereotopic C-17 methylene protons. Instead, the 1H NMR spectrum of **5** showed the presence of a singlet at δ_H 6.31 ppm, which correlated with a methine at δ_C 97.6 ppm in the gHSQC experiment, pointing to the presence of a hemiacetal ring. The hemiacetal proton was connected to the carbonyl carbon at δ_C 169.7 ppm in the gHMBC experiment, which allowed the additional acetyl group to be located at C-17.

Like **4**, in compound **5** all the hydroxy groups attached to the myrsinane skeleton were esterified with acetyl groups; this feature differentiates both of them from the myrsinanes previously described in the literature. The relative configuration of compound **5** was elucidated by comparison with reported myrsinane diterpenes^{27–29} and the correlations observed in the NOESY spectrum (Figure 5). NOESY




Figure 5. Selected NOESY correlations exhibited by **5**.

correlations observed for H-1 α /H-1 β , H-2 α /H₃-16 β , H-2 α /H-3 α , H-2 α /H-4 α , H-3 α /H-4 α , H-4 α /H-17, H-17/H-7 α , H-14 α /H-4 α , H-14 α /H-1 α , H-1 β /H₃-16 β , and H-5 β /H-12 β suggested that H-2, H-3, H-4, H-7, and H-14 are α -oriented and H-5, H-12, and H₃-16 are β -oriented (Figure 5). In turn, NOESY correlations observed for H-12 β /H₃-19, H₃-19/H-18a, H-18a/H-18b, H-18b/H-11 α , H-18b/H₃-20 β , H-11 α /H₃-20 β , H-11 α /H-9, H-9/H-8, and H-8/H-7 α confirmed that H-11 is α -oriented, as well as H-7, and that the only orientation compatible with those correlations for the methyl group substituted at C-13 is β (H₃-20 β). These correlations allowed compound **5** to be assigned structurally as (2*S**,3*S**,4*R**,5*R**,6*R**,7*R**,11*S**,12*R**,13*R**,14*S**,15*R**,17*S**)-3,5,7,14,15,17-hexacetoxy-14-deoxo-13,17-epoxymyrsinol.

Compounds **6** and **7** showed spectroscopic data closely related structurally to compound **8**,²¹ which possesses a cyclomyrsinane-type terpene skeleton. Cyclomyrsinanes are diterpenoids with a 5/7/6/4-tetracyclic or alternatively 5/7/6/4/5-pentacyclic carbon framework if a 13/17-epoxy is present. Both compounds (**6** and **7**) were isolated as amorphous solids. Their respective molecular formulas were determined as $C_{36}H_{48}O_{16}$ (m/z 759.2859 $[M + Na]^+$, calcd for $C_{36}H_{48}O_{16}Na$, 759.2840) and $C_{39}H_{46}O_{16}$ (m/z 793.2686 $[M +$

$Na]^+$, calcd for $C_{39}H_{46}O_{16}Na$, 793.2684), from their HRESIMS data. The 1H and ^{13}C NMR spectra of compounds **6** and **7** were similar (Table 3). A detailed analysis revealed the presence of signals corresponding to six acetoxy groups, one

Table 3. NMR Spectroscopic Data of Cyclomyrsinanes **6** (C_6D_6) and **7** ($CDCl_3$) (J in Hz)

position	6		7	
	δ_H (400 MHz)	δ_C (100 MHz), type	δ_H (500 MHz)	δ_C (125 MHz), type
1 α	2.42, dd (15.9, 9.9)	43.2, CH ₂	2.46, dd (16.0, 9.5)	42.9, CH ₂
1 β	3.05, dd (15.9, 8.8)		2.71, dd (16.0, 10.5)	
2 α	1.54, m	35.1, CH	2.19, m	35.9, CH
3 α	5.17, t (4.5)	76.9, CH	5.39, t (4.0)	76.9, CH
4 α	2.56, dd (11.2, 4.4)	52.0, CH	2.96, dd (4.0, 11.3)	51.5, CH
5 β	6.05, d (11.2)	68.8, CH	6.07, d (11.3)	67.8, CH
6		65.5, C		64.8, C
7		200.2, C		199.5, C
8 α	5.48, d (7.0)	71.2, CH	5.19, d (7.5)	73.5, CH
9 α	2.08, m	28.9, CH	2.90, m	29.2, CH
10		77.4, C		77.1, C
11 α	2.70, m	42.7, CH	2.82, m	42.6, CH
12 β	4.17, d (12.3)	39.6, CH	4.10, d (12.5)	38.9, CH
13		91.7, C		92.0, C
14 α	5.30, s	81.0, CH	5.12, s	80.5, CH
15		90.9, C		90.1, C
16 β	0.67, d (7.0)	14.2, CH ₃	0.85, d (7.0)	14.1, CH ₃
17	6.96, s	96.7, CH	6.53, s	96.6, CH
18 α	2.36, m	34.8, CH ₂	2.40, dd (10.0, 13.0) ^f	36.5, CH ₂
18 β	2.65, m		2.66, m ^f	
19 α	1.42, s	24.7, CH ₃	1.66, s	24.4, CH ₃
20 β	1.32, s	23.2, CH ₃	1.27, s	22.7, CH ₃
O $\underline{C}O$ -3		169.6, C		170.3, C
O $\underline{C}OMe$ -3	1.72, s	20.4, ^c CH ₃	2.02, s	20.9, CH ₃
O $\underline{C}O$ -5		170.0, C		169.7, C
O $\underline{C}OMe$ -5	1.81, s	20.6, ^c CH ₃	1.98, s	20.8, CH ₃
O $\underline{C}O$ -8		174.8, C		166.0, C
O $\underline{C}OiBu$ -8				
2'	2.78, sept (7.0)	34.7, CH		
3'	1.36, d (7.0) ^a	20.4, ^c CH ₃		
4'	1.10, d (7.0) ^a	18.9, ^c CH ₃		
8-OCOBz				
1'				129.9, C
2', 6'			8.22, d (8.0)	130.1, CH
4'			7.57, t (8.0)	133.4, CH
3', 5'			7.42, t (8.0)	128.4, CH
O $\underline{C}O$ -10		167.9, ^d C		168.3, ⁱ C
O $\underline{C}OMe$ -10	1.99, s ^b	23.3, ^e CH ₃	1.65, s ^g	23.2, ^j CH ₃
O $\underline{C}O$ -14		170.0, C		170.4, C
O $\underline{C}OMe$ -14	1.90, s	21.1, CH ₃	2.06, s	21.3, CH ₃
O $\underline{C}O$ -15		168.5, ^d C		169.1, ⁱ C
O $\underline{C}OMe$ -15	1.83, s ^b	21.4, ^e CH ₃	2.00, s ^{g,h}	21.3, ^j CH ₃
O $\underline{C}O$ -17		168.4, C		169.1, C
O $\underline{C}OMe$ -17	1.61, s	20.7, CH ₃	2.00, s ^h	21.7, ^j CH ₃

^{a–j}Interchangeable signals.

more than for **8**. Five of these acetoxy groups were assigned at C-3, C-5, C-10, C-14, and C-15 by comparison of the spectroscopic data of both compounds (**6** and **7**) with those of **8**.²¹ These assignments were corroborated through correlations observed in their gHMBC spectra. The remaining acetoxy group was attached at C-17 based on the observed correlation between the proton H-17 (δ_{H} 6.96 ppm in **6** and 6.53 ppm in **7**) and the carbonyl carbon OCO -17 (δ_{C} 168.4 ppm in **6** and 169.1 ppm in **7**) in the gHMBC spectra. Unlike myrsinanes and premysinanes, this is the first report of a hemiacetal ring in the cyclomyrsinanes.

In addition to these acetoxy groups, an ester group was present at position C-8 in both compounds. For compound **6**, the presence of two doublets at δ_{H} 1.10 and 1.36 ppm, each corresponding to a methyl group, connected to a septet at δ_{H} 2.78 ppm in the COSY experiment, pointed to the presence of an isobutyrate ester. On the other hand, compound **7** showed typical aromatic signals at δ_{H} 7.42, 7.57, and 8.22 in its ^1H NMR spectrum, suggesting the presence of a benzoyloxy group. The long-range coupling between H-8 (δ_{H} 5.48 ppm in **6** and 5.19 ppm in **7**) and OCO -8 (δ_{C} 174.8 ppm in **6** and 166.0 ppm in **7**) in the gHMBC spectra placed the ester groups at C-8 in both compounds.

The relative configurations of compounds **6** and **7** were elucidated on the basis of comparison with reported values for cyclomyrsinane diterpenes^{21,28,29} and the correlations observed in the NOESY experiments. NOESY correlations observed for H-2 α /H-3 α , H-2 α /H-4 α , H-3 α /H-4 α , H-4 α /H-17, H-4 α /H-14 α , H-14 α /H-1 α , H-8 α /H-9 α , H-9 α /H-18 α , H-9 α /H-11 α , H-11 α /H₃-19 α , and H-18 α /H₃-19 α in compound **6** revealed they have the same orientation as in compound **8**²¹ and suggested that H-2, H-3, H-4, H-8, H-9, H-11, H-14, and H₃-19 are α . On the other hand, NOESY correlations observed for H-1 α /H₃-16 β , H-2 α /H₃-16 β , H-5 β /H-12 β , and H-14 α /H₃-20 β confirmed, in turn, that H-5, H-12, H₃-16, and H₃-20 are β -oriented (Figure 6). These correlations allowed compound **6**




Figure 6. Selected NOESY correlations exhibited by **6**.

to be determined as (2*S**,3*S**,4*R**,5*R**,6*R**,8*R**,9*R**,10*S**,11*S**,12*R**,13*R**,14*S**,15*R**,17*S**)-3,5,10,14,15,17-hexa-acetoxy-8-isobutyryloxy-13,17-epoxycyclomyrsinol.

The NOESY correlations observed for H-2 α /H-3 α , H-2 α /H-4 α , H-3 α /H-4 α , H-4 α /H-17, H-4 α /H-14 α , and H-14 α /H-1 α in compound **7** revealed they also have the same relative configuration as in compound **8**²¹ and suggested that H-2, H-3, H-4, and H-14 are α -oriented. The NOESY correlations observed for H-1 α /H₃-16 β , H-2 α /H₃-16 β , H-5 β /H-12 β , H-14 α /H₃-20 β , H-2',6'/H-5 β , and H-2',6'/ OCOCH_2 -10 con-

firmed that H-5, H-12, H₃-16, H₃-20, and OCOCH_2 -10 are β -oriented. These observations, together with NOESY correlations between H-8 α /H-9 α and H-11 α /H₃-20 β , in turn, implied that H-8, H-9, H-11, and H₃-19 are α -oriented (Figure 7). Accordingly, compound **7** was assigned as (2*S**,3*S**,




Figure 7. Selected NOESY correlations exhibited by **7**.

4*R**,5*R**,6*R**,8*R**,9*R**,10*S**,11*S**,12*R**,13*R**,14*S**,15*R**,17*S**)-3,5,10,14,15,17-hexa-acetoxy-8-benzoyloxy-13,17-epoxycyclomyrsinol.

Electronic circular dichroism (ECD) spectra for compounds **2** and **7** were measured (see Figures S41 and S42, respectively, in the Supporting Information) and compared to those of prolifepene B and A, respectively.²⁵ Both series of ECD spectra show close resemblances, noting that the wavelength and sign of the observed Cotton effects presented similar patterns. Therefore, on this basis, the absolute configuration for compounds **2** and **3** can be assigned as 2*S*,3*S*,4*R*,5*R*,6*R*,7*S*,9*S*,11*S*,12*R*,13*S*,15*R*. On the other hand, the absolute configuration for compounds **6** and **7** can be proposed as 2*S*,3*S*,4*R*,5*R*,6*R*,8*R*,9*R*,10*S*,11*S*,12*R*,13*R*,14*S*,15*R*,17*S*.

As mentioned previously, lathyrane-type diterpenes are new drug candidates to modulate adult neurogenesis through PKC activation.¹⁶ Consequently, the effects of lathyrane compounds **9** and **10** were evaluated on NPC proliferation.

To this end, neurosphere assays were used, in which neural progenitor cells isolated from the subventricular zone of postnatal mice were cultured in the presence of growth factors. Under these conditions, cells grow as aggregates named neurospheres, initiated by a neurosphere-forming cell (stem cell or undifferentiated progenitor) and expanded by its progeny (undifferentiated progenitors, glial progenitors, and neuronal progenitors). The size and number of these neurospheres therefore are an indirect measure of NPC proliferation. In particular, the neurosphere size has been well described as an indicator of proliferation of neurosphere-forming cells (mostly undifferentiated progenitors), while the neurosphere number indicates self-renewal and neurosphere-initiating capacity of NPCs together with their viability. Experiments were performed in cultures stimulated with either the epidermal growth factor (EGF), the basic fibroblast growth factor (bFGF), or a combination of both. Increasing concentrations of **9** and **10** (1, 5, and 10 μM) were used to test proliferation. After 72 h, an increase was observed in the




Figure 8. Effects of increasing concentrations of **9** on neural precursor cell (NPC) proliferation in an in vitro assay. Proliferation was evaluated in a neurosphere assay in the presence of EGF (E), bFGF (F), or a combination of both (E+F). (A) Phase-contrast microscopic images of neurospheres cultured for 72 h in the absence or presence of **9** (1, 5, or 10 μM) plus the specific growth factor, or a combination of the two. The scale bar indicates 200 μm . (B) Graph showing the effect of increasing concentrations of **9** on neurosphere area after 72 h in culture. (C) Graph showing the effect of increasing concentrations of **9** on neurosphere number after 72 h in culture (* $p < 0.05$ compared with the control using a Student *t* test).

size of neurospheres in cultures stimulated with a combination of EGF and bFGF and treated with compound **9** when 5 and 10 μM concentrations were used, while no effect was observed at 1 μM (Figure 8A and B). Interestingly, these effects were only observed in cultures in which proliferation was stimulated by both growth factors, and no statistically significant effect was observed in cultures stimulated with either EGF or bFGF alone. These results indicated that **9** promotes NPC proliferation in a dose-dependent manner only when proliferation is stimulated by both growth factors. Nevertheless, no effect was found in neurosphere number, indicating that the capacity to form new neurospheres (self-renewal and viability) was not affected (Figure 8A and C).

Compound **10** induced a smaller increase in the neurosphere area and only at 5 μM and also in the presence of both growth factors. This compound (**10**) also did not exert any effect on neurosphere number (Figure 9A–C). These results indicated that the modes of action of both compounds were

probably similar, although **9** exerted a more potent effect on NPC proliferation compared to **10**.

In contrast, previous reports on the effect of lathyranes on NPC proliferation have described a proliferative effect only in the presence of bFGF or EGF alone, but not with a combination of them both.¹⁶ In particular, the lathyranes ELAC promotes NPC proliferation in a PKC β -dependent manner in cultures stimulated with bFGF, indicating a role for this lathyranes on activating classical PKC.¹⁶ These results have suggested a role for classical PKC on activating the epidermal growth factor receptor (EGFR) in bFGF-stimulated cultures and the basic fibroblast growth factor receptor (FGFR) in EGF-stimulated cultures. Thus, when both receptors are saturated by EGF and bFGF, no effect can be observed. This is in agreement with recent findings, which demonstrated that classical PKC activation facilitates the release of EGFR ligands such as TGF α .³⁰

Regarding the effect of the compounds tested herein, **9** and, to a lesser extent, **10** exerted a synergistic effect on NPC




Figure 9. Effects of **10** on neural precursor cell (NPC) proliferation in an in vitro assay. Proliferation was evaluated by a neurosphere assay in the presence of epidermal growth factor (EGF), basic fibroblastic growth (bFGF), or a combination of both. (A) Phase-contrast microscopic images of neurospheres cultured for 72 h in the absence or presence of **10** (1, 5, or 10 μM) plus the specific growth factor or the combination of the two. The scale bar indicates 200 μm . (B) Graph showing the effect of increasing concentrations of **10** on neurosphere area after 72 h in culture. (C) Graph showing the effect of increasing concentrations of **10** on neurosphere number after 72 h in culture (* $p < 0.05$ compared with the control using a Student t test).

proliferation when stimulated with a combination of EGF plus bFGF, suggesting they are acting on receptors different from EGFR or FGFR. Recent reports have shown that novel PKC activation facilitates the release of the ErbB4 receptor ligand neuregulin.³⁰ Therefore, it is possible that compounds **9** and **10** are activating novel PKC isozymes. This is a reasonable hypothesis since classical PKC isozymes have a C1B regulatory domain with a lower affinity for diacylglycerol (DAG) or its analogues, whereas the novel PKC C1B domain has a higher affinity.³¹ According to this, **9** and **10** may be able to activate novel PKCs without activating the classical isozymes, thus exerting an effect through a different signaling pathway.

EXPERIMENTAL SECTION

General Experimental Procedures. Optical rotations were determined with a PerkinElmer 341 polarimeter. IR spectra were recorded on a PerkinElmer Spectrum BX FT-IR spectrophotometer and reported as wavenumber (cm^{-1}). ECD spectra were recorded on a JASCO J-1500 CD spectrometer. ^1H and ^{13}C NMR measurements

were carried out on Agilent 400, 500, and 600 MHz spectrometers with SiMe_4 as the internal reference. Chemical shifts were referenced to CDCl_3 (δ_{H} 7.25, δ_{C} 77.0) and C_6D_6 (δ_{H} 7.15, δ_{C} 128.0). NMR assignments were made using a combination of 1D and 2D techniques and by comparison with those made for previously described compounds, where appropriate. High-resolution mass spectrometry (HRMS) was performed in a Q-TOF mass spectrometer in the positive-ion ESI mode. TLC was performed on Merck Kiesegel 60 F_{254} , 0.25 mm thick. Silica gel 60 (70–230 mesh, Merck) was used for column chromatography. HPLC was performed with a Merck-Hitachi LaChrom apparatus equipped with a UV-vis detector (L 4250) and a differential refractometer detector (RI-7490) and an Elite LaChrom-Hitachi apparatus equipped with a differential refractometer detector (RI-2490). LiChroCART LiChrospher Si 60 (5 μm , 250 mm \times 4 mm), LiChroCART LiChrospher Si 60 (10 μm , 250 mm \times 10 mm), and LiChroCART ChiraSpher NT, based on silica gel particles coated with the optically active polymer poly(*N*-acryloyl-*S*-phenylalanine ethyl ester), columns (5 μm , 250 mm \times 4 mm) were used for isolation experiments.

Plant Material. The whole plants of *E. boetica* were collected at El Pinar del Hierro in Chiclana de la Frontera, Cádiz, Spain, in June 2011 by Dr. L. Plaza-Aguirre (Consejería del Medio Ambiente of Junta de Andalucía) and J. Luis Rendón (Botanical Garden of San Fernando, Cádiz, Spain).

Extraction and Isolation. The aerial parts of the fresh plant (1.2 kg) were frozen with liquid nitrogen, powdered, and extracted with 2.5 L of MeOH (×3) at room temperature for 24 h. The MeOH extract was evaporated under reduced pressure to yield a crude extract (58.4 g), which was suspended in water (1 L) and then partitioned with hexane (2 L) and dichloromethane (1 L), sequentially. After removing the solvent, the hexane-soluble extract yielded 12.2 g of residue and 0.5 g of the dichloromethane-soluble extract. The residual aqueous fraction was freeze-dried. The hexane and dichloromethane extracts were chromatographed on silica gel in a gradient mixture of *n*-hexane–EtOAc of increasing polarity (0–100%), to afford 32 and 26 fractions, respectively, according to TLC analysis. Final purification of those fractions from the hexane extract that showed the presence of diterpene signals in their ¹H NMR spectra was carried out by means of semipreparative and/or analytical and/or chiral analytical HPLC. The hexane fraction yielded (per gram of hexane fraction) compounds **1** (0.5 mg), **2** (3.0 mg), **3** (0.5 mg), **4** (0.5 mg), **5** (2.0 mg), **6** (2.0 mg), **7** (0.5 mg), **8** (1.0 mg), **9** (13.0 mg), and **10** (30.0 mg). Fractions of the dichloromethane extract were analyzed by ¹H NMR, detecting the presence of compounds **2**, **3**, and **5–9**.

(2*S**,3*S**,4*R**,5*R**,6*R**,9*S**,11*S**,12*R**,13*R**,15*R**)-3,5,15-Triacetoxyl-13,17-epoxypremyrinsinol (**1**): amorphous solid; $[\alpha]_D^{20}$ –31 (c 0.13, CHCl₃); IR (film) ν_{\max} 2926, 1739, 1453, 1371, 1240, 1143, 1024, 967, 753 cm⁻¹; ¹H and ¹³C NMR data, see Table 1; gHMBC (selected correlations) C-1 → H₃-16β; C-2 → H-1α, H-1β; C-3 → H-1α, H₃-16β; C-4 → H-5β; C-5 → H-4α, H-12β, H-17a, H-17b; C-6 → H-12β; C-7 → H-17b; C-9 → H₃-18α, H₃-19β; C-10 → H-12β, H₃-18α, H₃-19β; C-11 → H-12β, H₃-18α, H₃-19β; C-13 → H-17a, H₃-20β; C-14 → H-12β, H₃-20β; C-15 → H-1β; C-18α → H₃-18β; C-19β → H₃-18α; OCO-5 → H-5β, OCOMe-5; HRESIMS *m/z* 499.2322 [M + Na]⁺ (calcd for C₂₆H₃₆O₈Na, 499.2308).

(2*S**,3*S**,4*R**,5*R**,6*R**,7*S**,9*S**,11*S**,12*R**,13*S**,15*R**)-3,7,13-Triacetoxyl-5-benzoyloxy-17-nicotinoyloxypremyrinsinol (**2**): amorphous solid; $[\alpha]_D^{20}$ –22 (c 0.26, CHCl₃); ECD (CH₃CN) λ (Δε) 203 (0.33), 214 (0.64), 234 (–0.74), 307 (0.18) nm; IR (film) ν_{\max} 3489, 2931, 1720, 1590, 1450, 1370, 1264, 1176, 1111, 1070, 964, 757, 713 cm⁻¹; ¹H and ¹³C NMR data, see Table 1; gHMBC (selected correlations) C-1 → H₃-16β; C-2 → H-1α, H-1β, H₃-16β; C-3 → H-1α, H₃-16β; C-4 → H-1α, H-5β, OH-15; C-5 → H-4α, H-7β, H-17a, H-17b; C-6 → H-4α, H-5β, H-7β, H-8β, H-12β, H-17a, H-17b; C-7 → H-5β, H-8β, H-9α, H-17a, H-17b; C-8 → H-7β; C-9 → H-7β, H-8β, H-8α; C-10 → H-12β, H₃-18α, H₃-19β; C-11 → H-8β, H-12β, H₃-18α, H₃-19β; C-12 → H-7β, H-17b, H₃-20α; C-13 → H-12β, H₃-20α; C-14 → H-1α, H-1β, H-4α, 15-OH, H₃-20α; C-15 → H-1α, H-1β, 15-OH; C-16β → H-1β; C-17 → H-5β, H-12β; C-18α → H₃-19β; C-19β → H₃-18α; C-20α → H-12β; OCOCH₃-3 → OCOCH₃-3; OCOPh-5 → H-5β, H₂-2',6'; OCOCH₃-7 → H-7β, OCOCH₃-7; OCOCH₃-13 → OCOCH₃-13; OCONic-17 → H-17a; HRESIMS *m/z* 742.2855 [M + Na]⁺ (calcd for C₃₉H₄₃NO₁₂Na, 742.2839).

(2*S**,3*S**,4*R**,5*R**,6*R**,7*S**,9*S**,11*S**,12*R**,13*S**,15*R**)-3,7,13-Triacetoxyl-5-isobutyroxy-17-nicotinoyloxypremyrinsinol (**3**): amorphous solid; $[\alpha]_D^{20}$ –16 (c 0.20, CHCl₃); IR (film) ν_{\max} 3486, 2937, 1739, 1590, 1422, 1371, 1249, 1139, 1072, 1022, 966, 754 cm⁻¹; ¹H and ¹³C NMR data, see Table 1; gHMBC (selected correlations) C-1 → H₃-16β; C-2 → H-1α, H-1β, H₃-16β; C-3 → H-1α, H₃-16β; C-4 → H-1α, H-5β, OH-15; C-5 → H-4α, H-7β, H-17a, H-17b; C-6 → H-4α, H-5β, H-7β, H-8β, H-12β, H-17a, H-17b; C-7 → H-5β, H-8β, H-9α, H-12β, H-17a, H-17b; C-8 → H-7β; C-9 → H-7β, H-8α, H-8β, H₃-18α, H₃-19β; C-10 → H-8β, H-12β, H₃-18α, H₃-19β; C-11 → H-8β, H-12β, H₃-18α, H₃-19β; C-12 → H-7β, H-17b, H₃-20α; C-13 → H-12β, H₃-20α; C-14 → H-1α, H-1β, H-4α, 15-OH, H₃-20α; C-15 → H-1α, H-1β, H-15β, OH-15; C-16β → H-1β; C-17 → H-5β, H-12β; C-18α → H-9α, H-11α, H₃-19β; C-19β → H₃-18α; C-20α → H-12β; OCOCH₃-3 → 3–OCOCH₃-3; OCOCH(CH₃)₂-5 → OCOCH(CH₃)₂-5; OCOCH(CH₃)₂-5 → OCOCH(CH₃)₂-5; OCOCH-

(CH₃)₂-5 → H-5β, OCOCH(CH₃)₂-5, OCOCH(CH₃)₂-5; COCH₃-7 → H-7β, COCH₃-7; COCH₃-13 → COCH₃-13; CONic-17 → H-17a, H-17b; HRESIMS *m/z* 708.3009 [M + Na]⁺ (calcd for C₃₆H₄₇NO₁₂Na, 708.2996).

(2*S**,3*S**,4*R**,5*R**,6*R**,7*R**,11*S**,12*R**,13*R**,14*S**,15*R**)-3,5,7,14,15-Pentaacetoxyl-14-deoxo-13,17-epoxymyrinsinol (**4**): colorless oil; $[\alpha]_D^{20}$ –13.4 (c 0.11, CHCl₃); IR (film) ν_{\max} 2939, 1740, 1370, 1233, 1083, 1040, 967, 753, 579 cm⁻¹; ¹H and ¹³C NMR data, see Table 2; gHMBC (selected correlations) C-3 → H-1α, H₃-16β; C-4 → H-1α, H-5β; C-5 → H-4α, H-7α, H-12β, H-17a, H-17b; C-6 → H-7α, H-8, H-11α, H-12β, H-17a; C-10 → H-11α, H-18b, H₃-19; C-11 → H-8, H-18a, H-18b, H₃-19; C-12 → H-7α, H-9, H-14α, H-17a, H₃-20; C-13 → H-11α, H-12β, H-14α, H-17a, H₃-20β; C-15 → H-1β; C-17 → H-5β, H-12β; C-19 → H-11α, H-18a, H-18b; OCOCH₃-5 → H-5β, OCOCH₃-5; OCOCH₃-7 → H-7α, OCOCH₃-7; OCOCH₃-4 → H-14α, OCOCH₃-14; HRESIMS *m/z* 599.2484 [M + Na]⁺ (calcd for C₃₀H₄₀O₁₁Na, 599.2468).

(2*S**,3*S**,4*R**,5*R**,6*R**,7*R**,11*S**,12*R**,13*R**,14*S**,15*R**,17*S**)-3,5,7,14,15,17-Hexaacetoxyl-14-deoxo-13,17-epoxymyrinsinol (**5**): amorphous solid; $[\alpha]_D^{20}$ –43 (c 0.10, CHCl₃); IR (film) ν_{\max} 2360, 1742, 1370, 1231, 1012 cm⁻¹; ¹H and ¹³C NMR data, see Table 2; gHMBC (selected correlations) C-1 → H-14α, H₃-16β; C-3 → H-1α, H₃-16β; C-4 → H-5β; C-5 → H-12β; C-6 → H-7α, H-8, H-12β; C-10 → H-12β, H-19; C-11 → H-9, H-12β, H-18a, H-18b, H₃-19; C-12 → H-7α, H-9, H-14α, H-17, H₃-20β; C-13 → H-14α, H-17, H-20β; C-15 → H-1β; C-17 → H-5β, H-12β; C-19 → H-18a, H-18b; OCOCH₃-5 → H-5β; OCOCH₃-7 → H-7α; OCOCH₃-14 → H-14α; OCOCH₃-17 → H-17; HRESIMS *m/z* 657.2524 [M + Na]⁺ (calcd for C₃₂H₄₂O₁₃Na, 657.2523).

(2*S**,3*S**,4*R**,5*R**,6*R**,8*R**,9*R**,10*S**,11*S**,12*R**,13*R**,14*S**,15*R**,17*S**)-3,5,10,14,15,17-Hexaacetoxyl-8-isobutyroxy-13,17-epoxycyclomyrinsinol (**6**): amorphous solid; $[\alpha]_D^{20}$ +58 (c 0.10, CHCl₃); IR (film) ν_{\max} 2930, 1742, 1370, 1230, 1105, 1009 cm⁻¹; ¹H and ¹³C NMR data see Table 3; gHMBC (selected correlations) C-1 → H-3α, H-14α, H₃-16β; C-2 → H-1α, H-1β, H₃-16β; C-3 → H-1α, H-5β; C-4 → H-1β, H-5β; C-5 → H-4α, H-12β, H-17; C-6 → H-4α, H-5β, H-8α, H-12β; C-7 → H-8α, H-12β; C-10 → H-11α, H-12β, H-18β, H₃-19α; C-11 → H-8α, H-12β, H₃-19α; C-12 → H-14α, H-17, H₃-20β; C-13 → H-14α, H-17, H₃-20β; C-14 → H-1α, H-4α, H-12β, H₃-20β; C-15 → H-1β, H-3α, H-14α; C-16 → H-1β; C-17 → H-5β, H-12β; C-18 → H₃-19α; OCO-3 → H-3α, OCOMe-3; OCO-5 → H-5β, OCOMe-5; OCO-8 → H-8α, H-2', H-3', H-4'; OCO-14 → H-14α, OCOMe-14; OCO-17 → H-17, OCOMe-17; HRESIMS *m/z* 759.2859 [M + Na]⁺ (calcd for C₃₆H₄₈O₁₆Na, 759.2840).

(2*S**,3*S**,4*R**,5*R**,6*R**,8*R**,9*R**,10*S**,11*S**,12*R**,13*R**,14*S**,15*R**,17*S**)-3,5,10,14,15,17-Hexaacetoxyl-8-benzoyloxy-13,17-epoxycyclomyrinsinol (**7**): amorphous solid; $[\alpha]_D^{20}$ +20 (c 0.10, CHCl₃); ECD (CH₃CN) λ (Δε) 204 (0.35), 229 (–0.48), 251 (0.24), 313 (0.99) nm; IR (film) ν_{\max} 2931, 1740, 1432, 1370, 1230, 1171, 1104, 1025, 965, 753, 718 cm⁻¹; ¹H and ¹³C NMR data, see Table 3; gHMBC (selected correlations) C-1 → H-3α, H-14α, H₃-16β; C-2 → H-1α, H-1β, H₃-16β; C-3 → H-1α, H-5β H₃-16β; C-4 → H-5β; C-5 → H-4α, H-12β, H-17; C-6 → H-12β; C-7 → H-8α; C-9 → H-18α; C-10 → H-12β, H₃-19α; C-11 → H-8α, H-12β, H₃-19α; C-12 → H-14α, H-17, H₃-20β; C-13 → H-14α, H-17, H₃-20β; C-14 → H-1α, H-4α, H-12β, H₃-20β; C-15 → H-1β, H-3α; C-16 → H-1β; C-17 → H-5β, H-12β; C-18 → H₃-19α; OCO-3 → H-3α, OCOMe-3 OCO-5 → H-5β, OCOMe-5; OCO-8 → H-2', H-6', H-8α; OCO-10ⁱ → 10–OCOMe-10^s; OCO-14 → H-14α, OCOMe-14; OCO-10ⁱ → OCOMe-15^{g,h}; OCO-17 → H-17, OCOMe-17^h (^{g,h,i} interchangeable signals); HRESIMS *m/z* 793.2686 [M + Na]⁺ (calcd for C₃₉H₄₆O₁₆Na, 793.2684).

Vertebrate Animals. For the NPC isolation from the subventricular zone (SVZ) 7-day-old mice were used. Animals were housed under controlled conditions (21–23 °C temperature and a light:dark cycle of 12:12), with water and food (AO4 standard maintenance diet; SAFE, Epinary-sur-Orge, France) ad libitum. Care and handling of animals were performed according to the Guidelines of the European Union Council (2010/63/EU) and Spanish Regulations 65/2012 and RD53/2013 for the use of laboratory

animals. All protocols that involved animals were approved by the “Dirección General de la Producción Agrícola y Ganadera” of the Andalusian “Consejería de Agricultura Pesca y Desarrollo Rural”, protocol number 30/03/2016/038i.

SVZ NPC Isolation and Culture. NPCs were obtained from the SVZ of 7-day-old postnatal mice following the same procedure described by Rabaneda et al.³² Six animals were used for each independent culture. Cultures of neurospheres were maintained in defined medium (DM) composed of Dulbecco’s modified Eagle’s medium/F12 medium (1:1 vol/vol) with 1 mg/L gentamicin (Gibco) and B27 supplement (Invitrogen, Carlsbad, CA, USA). EGF (20 ng/mL, Gibco) and bFGF (10 ng/mL, Peprotech, Frankfurt, Germany) were added on cultures to benefit the culture expansion.

Neurosphere Assays. To test the effects of compounds **9** and **10** on NPC proliferation, neurospheres were disaggregated mechanically to single cells and plated onto anti-adherent 96-well plates at a density of 20 000 cells/mL in DM supplemented with EGF (20 ng/mL) and bFGF (10 ng/mL), or only EGF, or only bFGF. Compounds **9** and **10** were added at the same time of seeding, and cells were cultured for 72 h. Triplicates of each condition were performed, and the experiments were done three independent times. Neurosphere number and size were measured as previously described by Rabaneda et al.³² using ImageJ software.

Statistical Analysis for in Vitro Experiments. Statistical analysis was performed using one-way ANOVA for more than two samples followed by a Bonferroni post-test. The Student’s *t* test was used when only one treatment group was compared with the control. Differences were considered significant at values of $p < 0.05$.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.jnatprod.9b00343](https://doi.org/10.1021/acs.jnatprod.9b00343).

1D and 2D NMR spectra of compounds **1–7**; ¹H and ¹³C NMR spectra for compounds **8–10**; ECD spectra for compounds **2** and **7** (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: carmen.castro@uca.es. Tel: +34 956 015252.

*E-mail: antoniojose.macias@uca.es. Tel: +34 956 012704.

ORCID

Rosa Durán-Patrón: 0000-0002-5307-4164

Antonio J. Macías-Sánchez: 0000-0001-6002-4977

Rosario Hernández-Galán: 0000-0003-1887-4796

Author Contributions

[†]Deceased February 18, 2019.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Dedicated to the late Dr. Maribel Murillo-Carretero. We thank her sincerely, for her very valuable work on the manuscript. This research was supported by the Spanish Consejería de Innovación, Ciencia y Empleo, Junta de Andalucía (grant no. P10CTS6639) and grants from MINECO (BFU2015-68652-R) and MCIU (RTI2018-099908-B-C22, MCIU/AEI/FEDER, EU). The use of NMR and MS facilities at the Servicios Centrales de Investigación Científica y Tecnológica (SC-ICYT) of the University of Cádiz is acknowledged. The authors are grateful to Dr. L. Plaza-Arregui (Consejería de Medio Ambiente of Junta de Andalucía) and J. Luis Rendón (Botanical Garden of San Fernando, Cádiz, Spain) for

collecting the plant material. The authors are grateful to Dr. Jose Manuel Botubol-Ares, for kindly measuring the ECD spectra for compounds **2** and **7**.

■ REFERENCES

- (1) Shi, Q.-W.; Su, X.-H.; Kiyota, H. *Chem. Rev.* **2008**, *108*, 4295–4327.
- (2) Vasas, A.; Hohmann, J. *Chem. Rev.* **2014**, *114*, 8579–8612.
- (3) Ernst, M.; Grace, O. M.; Saslis-Lagoudakis, C. H.; Nilsson, N.; Simonsen, H. T.; Rønsted, N. *J. Ethnopharmacol.* **2015**, *176*, 90–101.
- (4) Durán-Peña, M. J.; Botubol-Ares, J. M.; Collado, I. G.; Hernández-Galán, R. *Nat. Prod. Rep.* **2014**, *31*, 940–952.
- (5) Blumberg, P. M.; Deldos, K. B.; Dunn, J. A.; Jaken, S.; Leach, K. L.; Yeh, E. *Ann. N. Y. Acad. Sci.* **1983**, *407*, 303–315.
- (6) Szallasi, Z.; Blumberg, P. M. *Cancer Res.* **1991**, *51*, 5355–5360.
- (7) Szallasi, Z.; Krsmanovic, L.; Blumberg, P. M. *Cancer Res.* **1993**, *53*, 2507–2512.
- (8) Williams, S. A.; Greene, W. C. *Cytokine* **2007**, *39*, 63–74.
- (9) Andersen, R. J.; Ntie-Kang, F.; Tietjen, I. *Antiviral Res.* **2018**, *158*, 63–77.
- (10) Kulkosky, J.; Culnan, D. M.; Roman, J.; Dornadula, G.; Schnell, M.; Boyd, M. R.; Pomerantz, R. J. *Blood* **2001**, *98*, 3006–3015.
- (11) Trushin, S. A.; Bren, G. D.; Asin, S.; Pennington, K. N.; Paya, C. V.; Badley, A. D. *J. Virol.* **2005**, *79*, 9821–9830.
- (12) Márquez, N.; Calzado, M. A.; Sánchez-Duffhues, G.; Pérez, M.; Minassi, A.; Pagani, A.; Appendino, G.; Diaz, L.; Muñoz-Fernández, M. A.; Muñoz, E. *Biochem. Pharmacol.* **2008**, *75*, 1370–1380.
- (13) Daoubi, M.; Marquez, N.; Mazoir, N.; Benharref, A.; Hernández-Galán, R.; Muñoz, E.; Collado, I. G. *Bioorg. Med. Chem.* **2007**, *15*, 4577–4584.
- (14) Avila, L.; Perez, M.; Sanchez-Duffhues, G.; Hernández-Galán, R.; Muñoz, E.; Cabezas, F.; Quiñones, W.; Torres, F.; Echeverri, F. *Phytochemistry* **2010**, *71*, 243–248.
- (15) Geribaldi-Doldán, N.; Flores-Giubi, E.; Murillo-Carretero, M.; García-Bernal, F.; Carrasco, M.; Macías-Sánchez, A. J.; Domínguez-Riscart, J.; Verástegui, C.; Hernández-Galán, R.; Castro, C. *Int. J. Neuropsychopharmacol.* **2016**, *19* (pii), No. pyv085.
- (16) Murillo-Carretero, M.; Geribaldi-Doldán, N.; Flores-Giubi, E.; García-Bernal, F.; Navarro-Quiroz, E. A.; Carrasco, M.; Macías-Sánchez, A. J.; Herrero-Foncubierta, P.; Delgado-Ariza, A.; Verástegui, C.; Domínguez-Riscart, J.; Daoubi, M.; Hernández-Galán, R.; Castro, C. *Br. J. Pharmacol.* **2017**, *174*, 2373–2392.
- (17) Ferreira, M. J. U.; Ascenso, J. R.; Tavares, O. S. *J. Nat. Prod.* **1995**, *58*, 275–279.
- (18) Ferreira, M.-J. U.; Ascenso, J. R. *Phytochemistry* **1999**, *51*, 439–444.
- (19) Mónico, A.; Nim, S.; Duarte, N.; Rawal, M. K.; Prasad, R.; Di Pietro, A.; Ferreira, M.-J. U. *Bioorg. Med. Chem.* **2017**, *25*, 3278–3284.
- (20) Vieira, C.; Duarte, N.; Reis, M. A.; Spengler, G.; Madureira, A. M.; Molnár, J.; Ferreira, M.-J. U. *Bioorg. Med. Chem.* **2014**, *22*, 6392–6400.
- (21) Ahmad, V. U.; Jassbi, A. R. *J. Nat. Prod.* **1999**, *62*, 1016–1018.
- (22) Lu, J.; Li, G.; Huang, J.; Zhang, C.; Zhang, L.; Zhang, K.; Li, P.; Lin, R.; Wang, J. *Phytochemistry* **2014**, *104*, 79–88.
- (23) Esposito, M.; Nim, S.; Nothias, L.-F.; Gallard, J.-F.; Rawal, M. K.; Costa, J.; Roussi, F.; Prasad, R.; Di Pietro, A.; Paolini, J.; Litaudon, M. *J. Nat. Prod.* **2017**, *80*, 479–487.
- (24) Ahmad, V. U.; Jassbi, A. R. *Phytochemistry* **1998**, *48*, 1217–1220.
- (25) Xu, J.; Kang, J.; Cao, X.; Sun, X.; Yu, S.; Zhang, X.; Sun, H.; Guo, Y. *J. Agric. Food Chem.* **2015**, *63*, 5902–5910.
- (26) Appendino, G.; Belloro, E.; Tron, G. C.; Jakupovic, J.; Ballero, M. *J. Nat. Prod.* **1999**, *62*, 1399–1404.
- (27) Jeske, F.; Jakupovic, J.; Berendsohn, W. *Phytochemistry* **1995**, *40*, 1743–1750.
- (28) Xu, J.; Guo, Y.; Xie, C.; Li, Y.; Gao, J.; Zhang, T.; Hou, W.; Fang, L.; Gui, L. *J. Nat. Prod.* **2011**, *74*, 2224–2230.

- (29) Öksüz, S.; Gürek, F.; Qiu, S.-X.; Cordell, G. A. *J. Nat. Prod.* **1998**, *61*, 1198–1201.
- (30) Dang, M.; Armbruster, N.; Miller, M. A.; Cermeno, E.; Hartmann, M.; Bell, G. W.; Root, D. E.; Lauffenburger, D. A.; Lodish, H. F.; Herrlich, A. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 9776–9781.
- (31) Newton, A. C. *Crit. Rev. Biochem. Mol. Biol.* **2018**, *53*, 208–230.
- (32) Rabaneda, L. G.; Carrasco, M.; López-Toledano, M. A.; Murillo-Carretero, M.; Ruiz, F. A.; Estrada, C.; Castro, C. *FASEB J.* **2008**, *22*, 3823–3835.